Meeder Asset Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,627
| Closed | -$86K | – | 2413 |
|
|
2020
Q3 | $86K | Hold |
1,627
| – | – | 0.01% | 828 |
|
|
2020
Q2 | $98K | Hold |
1,627
| – | – | 0.01% | 764 |
|
|
2020
Q1 | $92K | Buy |
1,627
+924
| +131% | +$52.7K | 0.01% | 735 |
|
|
2019
Q4 | $40K | Sell |
703
-1,571
| -69% | -$83.3K | ﹤0.01% | 1100 |
|
|
2019
Q3 | $122K | Buy |
2,274
+206
| +10% | +$12K | 0.01% | 745 |
|
|
2019
Q2 | $123K | Sell |
2,068
-204
| -9% | -$12.8K | 0.01% | 704 |
|
|
2019
Q1 | $141K | Hold |
2,272
| – | – | 0.01% | 618 |
|
|
2018
Q4 | $138K | Sell |
2,272
-72
| -3% | -$4.3K | 0.01% | 573 |
|
|
2018
Q3 | $137K | Buy |
2,344
+1,056
| +82% | +$53.9K | 0.01% | 575 |
|
|
2018
Q2 | $57.8K | Buy |
1,288
+300
| +30% | +$12.9K | 0.01% | 722 |
|
|
2018
Q1 | $44K | Buy |
988
+501
| +103% | +$21K | ﹤0.01% | 705 |
|
|
2017
Q4 | $21K | Buy |
487
+406
| +501% | +$18.2K | ﹤0.01% | 918 |
|
|
2017
Q3 | $4K | Hold |
81
| – | – | ﹤0.01% | 1344 |
|
|
2017
Q2 | $4K | Buy |
81
+64
| +376% | +$3.35K | ﹤0.01% | 1290 |
|
|
2017
Q1 | $1K | Buy |
+17
| New | +$900 | ﹤0.01% | 1595 |
|
Other funds holding BSTC
Meeder Asset Management's BSTC Position: Q4 2020 in Review
Meeder Asset Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 1,627 shares — an estimated $86K sold.
Meeder Asset Management first reported a position in BSTC in Q1 2017 and held it in 15 quarters. The position peaked at $141K in Q1 2019. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.
- Meeder Asset Management reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
- Meeder Asset Management sold 1,627 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $86K.
- Meeder Asset Management first reported a position in BioSpecifics Technologies Corp. in Q1 2017 and held it in 15 quarters.
- Meeder Asset Management's BioSpecifics Technologies Corp. position peaked at $141K in Q1 2019.
- 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.
Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.